Literature DB >> 11737161

Alcohol and marijuana: effects on epilepsy and use by patients with epilepsy.

E Gordon1, O Devinsky.   

Abstract

We review the safety of alcohol or marijuana use by patients with epilepsy. Alcohol intake in small amounts (one to two drinks per day) usually does not increase seizure frequency or significantly affect serum levels of antiepileptic drugs (AEDs). Adult patients with epilepsy should therefore be allowed to consume alcohol in limited amounts. However, exceptions may include patients with a history of alcohol or substance abuse, or those with a history of alcohol-related seizures. The most serious risk of seizures in connection with alcohol use is withdrawal. Alcohol withdrawal lowers the seizure threshold, an effect that may be related to alcohol dose, rapidity of withdrawal, and chronicity of exposure. Individuals who chronically abuse alcohol are at significantly increased risk of developing seizures, which can occur during withdrawal or intoxication. Alcohol abuse predisposes to medical and metabolic disorders that can lower the seizure threshold or cause symptoms that mimic seizures. Therefore, in evaluating a seizure in a patient who is inebriated or has abused alcohol, one must carefully investigate to determine the cause. Animal and human research on the effects of marijuana on seizure activity are inconclusive. There are currently insufficient data to determine whether occasional or chronic marijuana use influences seizure frequency. Some evidence suggests that marijuana and its active cannabinoids have antiepileptic effects, but these may be specific to partial or tonic-clonic seizures. In some animal models, marijuana or its constituents can lower the seizure threshold. Preliminary, uncontrolled clinical studies suggest that cannabidiol may have antiepileptic effects in humans. Marijuana use can transiently impair short-term memory, and like alcohol use, may increase noncompliance with AEDs. Marijuana use or withdrawal could potentially trigger seizures in susceptible patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11737161     DOI: 10.1046/j.1528-1157.2001.19301.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  37 in total

1.  Convulsions associated with the use of a synthetic cannabinoid product.

Authors:  Aaron B Schneir; Todd Baumbacher
Journal:  J Med Toxicol       Date:  2012-03

2.  Dietary approaches to epilepsy treatment: old and new options on the menu.

Authors:  Carl E Stafstrom
Journal:  Epilepsy Curr       Date:  2004 Nov-Dec       Impact factor: 7.500

3.  Kindling modifies morphine, cocaine and ethanol place preference.

Authors:  Axel Becker; Marco Schmitz; Gisela Grecksch
Journal:  Exp Brain Res       Date:  2005-08-11       Impact factor: 1.972

4.  Medical Marijuana for Epilepsy?

Authors:  Murali K Kolikonda; Kavitha Srinivasan; Manasa Enja; Vishwanath Sagi; Steven Lippmann
Journal:  Innov Clin Neurosci       Date:  2016-04-01

Review 5.  Functional Relevance of Endocannabinoid-Dependent Synaptic Plasticity in the Central Nervous System.

Authors:  Shana M Augustin; David M Lovinger
Journal:  ACS Chem Neurosci       Date:  2018-02-19       Impact factor: 4.418

Review 6.  Pharmacokinetics and pharmacodynamics of cannabinoids.

Authors:  Franjo Grotenhermen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 7.  [Therapeutic use of cannabinoids in neurology].

Authors:  P Schwenkreis; M Tegenthoff
Journal:  Schmerz       Date:  2003-10       Impact factor: 1.107

Review 8.  Seizures in alcohol-dependent patients: epidemiology, pathophysiology and management.

Authors:  Matti Hillbom; Ilkka Pieninkeroinen; Maurizio Leone
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

9.  Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo.

Authors:  Nicholas A Jones; Andrew J Hill; Imogen Smith; Sarah A Bevan; Claire M Williams; Benjamin J Whalley; Gary J Stephens
Journal:  J Pharmacol Exp Ther       Date:  2009-11-11       Impact factor: 4.030

Review 10.  Cannabinoids and Epilepsy.

Authors:  Evan C Rosenberg; Richard W Tsien; Benjamin J Whalley; Orrin Devinsky
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.